Innovative therapeutics

Investors

SEC Filings

NASDAQBMRN
FormDescriptionDateFormat
4Statement of changes in beneficial ownership of securitiesMay 14, 2018View HTMLDownload DOCDownload PDF
4Statement of changes in beneficial ownership of securitiesMay 14, 2018View HTMLDownload DOCDownload PDF
4Statement of changes in beneficial ownership of securitiesMay 9, 2018View HTMLDownload DOCDownload PDF
4/AAmendment to a previously filed 4Apr 27, 2018View HTMLDownload DOCDownload PDF
4/AAmendment to a previously filed 4Apr 27, 2018View HTMLDownload DOCDownload PDF
4/AAmendment to a previously filed 4Apr 27, 2018View HTMLDownload DOCDownload PDF
4/AAmendment to a previously filed 4Apr 27, 2018View HTMLDownload DOCDownload PDF
4/AAmendment to a previously filed 4Apr 27, 2018View HTMLDownload DOCDownload PDF
4/AAmendment to a previously filed 4Apr 27, 2018View HTMLDownload DOCDownload PDF
10-QQuarterly report which provides a continuing view of a company's financial positionApr 27, 2018View HTMLDownload DOCDownload PDFDownload XLSView XBRLDownload XBRL
4/AAmendment to a previously filed 4Apr 26, 2018View HTMLDownload DOCDownload PDF
4/AAmendment to a previously filed 4Apr 26, 2018View HTMLDownload DOCDownload PDF
4/AAmendment to a previously filed 4Apr 26, 2018View HTMLDownload DOCDownload PDF
4/AAmendment to a previously filed 4Apr 26, 2018View HTMLDownload DOCDownload PDF
4/AAmendment to a previously filed 4Apr 26, 2018View HTMLDownload DOCDownload PDF
4/AAmendment to a previously filed 4Apr 26, 2018View HTMLDownload DOCDownload PDF
4Statement of changes in beneficial ownership of securitiesApr 25, 2018View HTMLDownload DOCDownload PDF
4Statement of changes in beneficial ownership of securitiesApr 25, 2018View HTMLDownload DOCDownload PDF
8-KReport of unscheduled material events or corporate eventApr 25, 2018View HTMLDownload DOCDownload PDFDownload XLS
4Statement of changes in beneficial ownership of securitiesApr 24, 2018View HTMLDownload DOCDownload PDF
DEF 14AOfficial notification to shareholders of matters to be brought to a vote ("Proxy")Apr 24, 2018View HTMLDownload DOCDownload PDFDownload XLS
DEFA14AAdditional proxy soliciting materials - definitiveApr 24, 2018View HTMLDownload DOCDownload PDFDownload XLS
4Statement of changes in beneficial ownership of securitiesApr 19, 2018View HTMLDownload DOCDownload PDF
4Statement of changes in beneficial ownership of securitiesApr 9, 2018View HTMLDownload DOCDownload PDF
4Statement of changes in beneficial ownership of securitiesApr 3, 2018View HTMLDownload DOCDownload PDF
1-25      26-50      51-75      76-100      101-125      126-137

BioMarin

Diseases

Lysosomal Storage Disorders (MPS I, MPS IVA, MPS VI, CLN2 disease) PKU, LEMS

Products

Brineura™
Vimizim®
Kuvan®
Naglazyme®
Aldurazyme®
Firdapse®

Patient/Physician Support Contact Information

BioMarin RareConnections
Tel: 866.906.6100
Fax: 888.863.3361
E-mail: support@biomarin-rareconnections.com

Global Medical Information

Contact Global Medical Information